Sign in
CompletedPhase 4

Sequenced Treatment Effectiveness for Posttraumatic Stress

Key facts

Who runs it
University of Washington
Where
Ann Arbor, Aurora, Bedford, Charleston, Cincinnati, Hancock, Missoula, North Little Rock, Portland, San Diego, SeaTac, Temperance, West Memphis, and Wichita Falls, United StatesSee the 15 sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
700 people enrolled
Started
1 Jun 2020
Ended
1 Aug 2024
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Selective serotonin reuptake inhibitor
  • Serotonin-norepinephrine reuptake inhibitor
  • Written Exposure Therapy
Record updated
8 May 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Screen positive for PTSD (PC-PTSD>=3 AND PCL>=33)
  • Screen positive for trauma (Brief Trauma questionnaire)

Who cannot take part

  • Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder or dementia
  • <18 years of age
  • Current prescription of venlafaxine
  • Change in any psychotropic prescription in the past 2 months
  • A scheduled specialty mental health appointment or preference for specialty mental health care
  • Pregnant
  • Terminally ill
  • Prisoner
  • Unable to communicate in English or Spanish
  • Impaired decision making capacity

Where in United States

  • Ann Arbor VA Medical CenterAnn Arbor, United States
  • VA Eastern Colorado Health CareAurora, United States
  • Bedford VA Medical CenterBedford, United States
  • Ralph H. Johnson VA Medical CenterCharleston, United States
  • Cincinnati VA Medical CenterCincinnati, United States
  • Upper Great Lakes Family Health CenterHancock, United States
  • Partnership Health CenterMissoula, United States
  • Little Rock VA Medical CenterNorth Little Rock, United States
  • Portland VA Medical CenterPortland, United States
  • Neighborhood HealthcareSan Diego, United States
  • San Diego VA Medical CenterSan Diego, United States
  • HealthpointSeaTac, United States
  • Family Medical Center of MichiganTemperance, United States
  • East Arkansas Family Health CenterWest Memphis, United States
  • North Central Texas Community Health CenterWichita Falls, United States

About the trial

What the trial wants to find out

Individuals with PTSD are more likely to engage in unhealthy behaviors such as tobacco use, drug use, alcohol misuse, and have high rates of morbidity/mortality. PTSD negatively impacts marriages, educational attainment, and occupational functioning. Some patients with PTSD can be successfully referred to specialty mental health clinics, but most patients with PTSD cannot engage in specialty care because of geographical, financial and cultural barriers and must be treated in primary care. However, policy makers do not know the best way to treat PTSD in primary care clinics, especially for patients who do not respond to the initial treatment choice. There are effective treatments for PTSD that are feasible to deliver in primary care. These treatments include commonly prescribed antidepressants and brief exposure-based therapies. However, because there are no head-to-head comparisons between pharmacotherapy and psychotherapy in primary care settings, primary care providers do not know which treatments to recommend to their patients. In addition, despite high treatment non-response rates, very few studies have examined which treatment should be recommend next when patients do not respond well to the first, and no such studies have been conducted in primary care settings.

Read full original descriptionShow less

This trial will be conducted in Federally Qualified Health Centers and VA Medical Centers, where the prevalence of both past trauma exposure and PTSD are particularly high. The investigators will enroll 700 primary care patients. The investigators propose to 1) compare outcomes among patients randomized to initially receive pharmacotherapy or brief psychotherapy, 2) compare outcomes among patients randomized to treatment sequences (i.e., switching and augmenting) for patients not responding to the initial treatment and 3) examine variation in treatment outcomes among different subgroups of patients. Telephone and web surveys will be used to assessed outcomes important to patients, like self-reported symptom burden, side-effects, health related quality of life, and recovery outcomes, at baseline, 4 and 8 months. Results will help patients and primary care providers choose which treatment to try first and which treatment to try second if the first is not effective.

The 3 groups in the trial

  • SSRI Then Augmentation by WETExisting treatment, for comparison

    Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment augmented by Written Exposure Therapy (WET) delivered by an integrated behavioral health consultant.

    Treatment: Selective serotonin reuptake inhibitor and Written Exposure Therapy

  • SSRI Then Switch to SNRIExisting treatment, for comparison

    Prescribers will prescribe one of three SSRIs (sertraline, fluoxetine or paroxetine). Patients who do not respond to treatment by four months will have their treatment switched to the SNRI (serotonin-norepinephrine reuptake Inhibitor) venlafaxine.

    Treatment: Selective serotonin reuptake inhibitor and Serotonin-norepinephrine reuptake inhibitor

  • WET Then Switch to SSRIExisting treatment, for comparison

    Integrated behavioral health consultants will deliver WET. Patients who do not respond to treatment by four months will be switched to one of three SSRIs (sertraline, fluoxetine or paroxetine).

    Treatment: Selective serotonin reuptake inhibitor and Written Exposure Therapy

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparative Effectiveness PTSD Trial of Sequenced Pharmacotherapy and Psychotherapy in Primary Care
Publications
Record updated
8 May 2025